betaferon for injection 0.25 mg/ml
bayer (south east asia) pte ltd - interferon beta-1b - injection, powder, for solution - 0.25 mg/ml
extavia 300microgram powder and solvent for solution for injection vials
novartis pharmaceuticals uk ltd - interferon beta-1b - powder and solvent for solution for injection - 300microgram
betaferon
bayer israel ltd - interferon beta 1b - powder and solvent for solution for injection - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
extavia
novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm
betaferon
bayer ag - interferon beta-1b - multiple sclerosis - immunostimulants, - betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.
extavia
novartis europharm limited - interferon beta-1b - multiple sclerosis - immunostimulants, - extavia is indicated for the treatment of:patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.
betaseron powder for solution
bayer inc - interferon beta-1b - powder for solution - 0.3mg - interferon beta-1b 0.3mg - immunomodulatory agents
extavia powder for solution
novartis pharmaceuticals canada inc - interferon beta-1b - powder for solution - 0.3mg - interferon beta-1b 0.3mg - immunomodulatory agents
betaferon 300microgram powder and solvent for solution for injection vials
bayer plc - interferon beta-1b - powder and solvent for solution for injection - 300microgram
betaferon inj 0.25mg/ml 0.25 mg/ml
شركة مستودع الأدوية الأردني - the jordan drugstore co - interferon beta-1b 0.25 mg/ml - 0.25 mg/ml